0 CHECKOUT

Thromboembolism - Pipeline Review, H2 2015

  • ID: 3387858
  • July 2015
  • 100 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Bayer AG
  • Cereno Scientific AB
  • Gamma Therapeutics, Inc.
  • GlycoMimetics, Inc.
  • Green Cross Corporation
  • Sanofi
  • MORE

Thromboembolism - Pipeline Review, H2 2015

Summary

The report ‘Thromboembolism - Pipeline Review, H2 2015’, provides an overview of the Thromboembolism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer AG
  • Cereno Scientific AB
  • Gamma Therapeutics, Inc.
  • GlycoMimetics, Inc.
  • Green Cross Corporation
  • Sanofi
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Thromboembolism Overview
Therapeutics Development
Pipeline Products for Thromboembolism - Overview
Pipeline Products for Thromboembolism - Comparative Analysis
Thromboembolism - Therapeutics under Development by Companies
Thromboembolism - Therapeutics under Investigation by Universities/Institutes
Thromboembolism - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Thromboembolism - Products under Development by Companies
Thromboembolism - Products under Investigation by Universities/Institutes
Thromboembolism - Companies Involved in Therapeutics Development
Bayer AG
Cereno Scientific AB
China Biologic Products, Inc.
Daiichi Sankyo Company, Limited
Gamma Therapeutics, Inc.
GlycoMimetics, Inc.
Green Cross Corporation
Isis Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
Sanofi
The International Biotechnology Center (IBC) “Generium”
Tobira Therapeutics, Inc.
Thromboembolism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
alteplase biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
antithrombin III (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
betrixaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gammarin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GCC-2107 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GMI-1271 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-FXIRx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lysimab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Protein for Thromboembolism - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REG-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rivaroxaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
semuloparin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit HDAC for Thromboembolism - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAP-ANV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YG-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thromboembolism - Recent Pipeline Updates
Thromboembolism - Dormant Projects
Thromboembolism - Discontinued Products
Thromboembolism - Product Development Milestones
Featured News & Press Releases
Jul 12, 2015: NICE recommends edoxaban tosylate (Lixiana) for treating and preventing potentially fatal blood clots
Jun 18, 2015: Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer
Jun 03, 2015: NICE guidance recommends apixaban (Eliquis) for treating and preventing potentially fatal blood clots
Apr 27, 2015: Daiichi Sankyo’s Once-Daily Lixiana (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe
Apr 15, 2015: Daiichi Sankyo’s Once-Daily Lixiana (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland
Mar 06, 2015: NICE draft guidance recommends apixaban (Eliquis) for treating and preventing potentially fatal blood clots
Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO
Dec 08, 2014: Daiichi Sankyo Launches New Formulation of LIXIANA 60 mg Tablets (edoxaban) in Japan
Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Thromboembolism, H2 2015
Number of Products under Development for Thromboembolism - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Thromboembolism - Pipeline by Bayer AG, H2 2015
Thromboembolism - Pipeline by Cereno Scientific AB, H2 2015
Thromboembolism - Pipeline by China Biologic Products, Inc., H2 2015
Thromboembolism - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Thromboembolism - Pipeline by Gamma Therapeutics, Inc., H2 2015
Thromboembolism - Pipeline by GlycoMimetics, Inc., H2 2015
Thromboembolism - Pipeline by Green Cross Corporation, H2 2015
Thromboembolism - Pipeline by Isis Pharmaceuticals, Inc., H2 2015
Thromboembolism - Pipeline by Portola Pharmaceuticals, Inc., H2 2015
Thromboembolism - Pipeline by Sanofi, H2 2015
Thromboembolism - Pipeline by The International Biotechnology Center (IBC) “Generium”, H2 2015
Thromboembolism - Pipeline by Tobira Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Thromboembolism Therapeutics - Recent Pipeline Updates, H2 2015
Thromboembolism - Dormant Projects, H2 2015
Thromboembolism - Discontinued Products, H2 2015

List of Figures
Number of Products under Development for Thromboembolism, H2 2015
Number of Products under Development for Thromboembolism - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Bayer AG
Cereno Scientific AB
China Biologic Products, Inc.
Daiichi Sankyo Company, Limited
Gamma Therapeutics, Inc.
GlycoMimetics, Inc.
Green Cross Corporation
Isis Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
Sanofi
The International Biotechnology Center (IBC) “Generium”
Tobira Therapeutics, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Cytori Therapeutics, Inc.
  • Pfizer Inc.
  • Medtronic, Inc.
  • St. Jude Medical, Inc.
  • Novo Nordisk A/S
  • Lumedx